Skip to main content

Table 1 Clinical and pathologic characteristics of the study cohort

From: Nuclear IRF-1 expression as a mechanism to assess “Capability” to express PD-L1 and response to PD-1 therapy in metastatic melanoma

   All patients IRF-1 High IRF-1 Low
N   47 31 16
Median age at diagnosis   62 63 60
Sex Male 24 14 10
Female 23 17 6
Race White 44 30 14
Black 2 0 2
Hispanic 1 1 0
Treatment Pembrolizumab 18 12 6
Nivolumab 10 4 6
Ipilimumab + nivolumab 19 15 4
Prior checkpoint blockade Yes 16 11 5
No 31 20 11
Mutation status BRAF 16 11 5
NRAS 6 5 1
CKIT 2 2 0
None detected 23 13 10
Stage at diagnosis I 5 3 2
II 8 5 3
III 17 11 6
IV 11 8 3
Unknown 6 4 2